Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis

References

• Ahnfelt-RonneINielsenOHChristensenAClinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acidGastroenterology199098116291969825
   PubMed Web of Science ®Google Scholar
• ArdizzoneSDoldoPRanziTMesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study groupItal J Gastroenterol Hepatol1999316778410730559
   PubMed Web of Science ®Google Scholar
• BaronJHConnellAMLennard-JonesJESulphasalazine and salicylazosulphadimidine in ulcerative colitisLancet196211094613865153
   PubMed Web of Science ®Google Scholar
• BurressGCMuschMWJurivichDAEffects of mesalamine on the hsp72 stress response in rat IEC-18 intestinal epithelial cellsGastroenterology1997113147499352849
   PubMed Web of Science ®Google Scholar
• CasellasFArenasJIBaudetJSImpairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter studyInflamm Bowel Dis2005114889615867589
   PubMed Web of Science ®Google Scholar
• CasellasFLopez-VivancosJBadiaXInfluence of inflammatory bowel disease on different dimensions of quality of lifeEur J Gastroenterol Hepatol2001135677211396538
   PubMed Web of Science ®Google Scholar
• CohenRDReview article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitisAliment Pharmacol Ther2006244657416886912
   PubMed Web of Science ®Google Scholar
• CohenRDWosethDMThistedRAA meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitisAm J Gastroenterol20009512637610811338
   PubMed Web of Science ®Google Scholar
• CourtneyMGNunesDPBerginCFRandomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitisLancet19923391279811349676
   PubMed Web of Science ®Google Scholar
• d’AlbasioGPaciniFCamarriECombined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind studyAm J Gastroenterol199792114379219787
   PubMed Web of Science ®Google Scholar
• D’HaensGHommesDEngelsLOnce daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging studyAliment Pharmacol Ther20062410879716984503
   PubMed Web of Science ®Google Scholar
• De VosMVerdievelHSchoonjansRConcentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparationsGut1992331338421446856
   PubMed Web of Science ®Google Scholar
• DickAPGraysonMJCarpenterRGControlled trial of sulphasalazine in the treatment of ulcerative colitisGut196454374214218553
   PubMed Web of Science ®Google Scholar
• EadenJAAbramsKRMayberryJFThe risk of colorectal cancer in ulcerative colitis: a meta-analysisGut2001485263511247898
   PubMed Web of Science ®Google Scholar
• FallingborgJChristensenLAIngeman-NielsenMpH-profile and regional transit times of the normal gut measured by a radiotelemetry deviceAliment Pharmacol Ther19893605132518873
   PubMed Web of Science ®Google Scholar
• FallingborgJChristensenLAJacobsenBAVery low intraluminal colonic pH in patients with active ulcerative colitisDig Dis Sci1993381989938223071
   PubMed Web of Science ®Google Scholar
• FarmerRGEasleyKARankinGBClinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patientsDig Dis Sci1993381137468508710
   PubMed Web of Science ®Google Scholar
• FlorenCHBenoniCWillenRHistologic and colonoscopic assessment of disease extension in ulcerative colitisScand J Gastroenterol198722459623602926
   PubMed Web of Science ®Google Scholar
• FrieriGGiacomelliRPimpoMMucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitisGut200047410410940280
   PubMed Web of Science ®Google Scholar
• FrieriGPimpoMTPalumboGCRectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatmentAliment Pharmacol Ther1999131413710571596
   PubMed Web of Science ®Google Scholar
• GendreJPMaryJYFlorentCOral mesalamine (Pentasa) as maintenance treatment in Crohn’s disease: a multicenter placebo-controlled study. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID)Gastroenterology199310443598425685
   PubMed Web of Science ®Google Scholar
• GhoshSShandAFergusonAUlcerative colitisBMJ200032011192310775225
   PubMed Web of Science ®Google Scholar
• GiafferMHHoldsworthCDLennard-JonesJEImproved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/dayAliment Pharmacol Ther19926479851358234
   PubMed Web of Science ®Google Scholar
• GionchettiPArdizzoneSBenvenutiMEA new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trialAliment Pharmacol Ther199913381810102972
   PubMed Web of Science ®Google Scholar
• GreenJRGibsonJAKerrGDMaintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 12 g daily over 12 months. ABACUS Investigator groupAliment Pharmacol Ther1998121207169882028
   PubMed Web of Science ®Google Scholar
• GreenJRLoboAJHoldsworthCDBalsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator GroupGastroenterology199811415229428213
   PubMed Web of Science ®Google Scholar
• GreenJRSwanCHGibsonJAPatient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational studyAliment Pharmacol Ther2004194354214871283
   PubMed Web of Science ®Google Scholar
• HanauerSGoodLIGoodmanMWLong-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitisAm J Gastroenterol20009517495410925979
   PubMed Web of Science ®Google Scholar
• HanauerSBSandbornWJKornbluthADelayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trialAm J Gastroenterol2005111001124788516279903
   PubMed Web of Science ®Google Scholar
• HanauerSSchwartzJRobinsonMMesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study GroupAm J Gastroenterol1993881188978338086
   PubMed Web of Science ®Google Scholar
• HawkeyCJBoughton-SmithNKWhittleBJModulation of human colonic arachidonic acid metabolism by sulfasalazineDig Dis Sci198530116152866075
   PubMed Web of Science ®Google Scholar
• HendriksenCKreinerSBinderVLong term prognosis in ulcerative colitis – based on results from a regional patient group from the county of CopenhagenGut198526158633967834
   PubMed Web of Science ®Google Scholar
• KammMASandbornWJGassullMOnce-daily, high-concentration MMX mesalamine in active ulcerative colitisGastroenterology2007132667517241860
   PubMed Web of Science ®Google Scholar
• KaneSHuoDAikensJMedication nonadherence and the outcomes of patients with quiescent ulcerative colitisAm J Med2003114394312543288
   PubMed Web of Science ®Google Scholar
• KaneSHuoDMagnantiKA pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitisClin Gastroenterol Hepatol20031170315017487
   PubMed Web of Science ®Google Scholar
• KaneSVCohenRDAikensJEPrevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitisAm J Gastroenterol20019629293311693328
   PubMed Web of Science ®Google Scholar
• KovvaliGDasKMMolecular mimicry may contribute to pathogenesis of ulcerative colitisFEBS Lett20055792261615848155
   PubMed Web of Science ®Google Scholar
• KruisWJudmaierGKayassehLDouble-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitisEur J Gastroenterol Hepatol1995739167614099
   PubMed Web of Science ®Google Scholar
• LangholzEMunkholmPDavidsenMChanges in extent of ulcerative colitis: a study on the course and prognostic factorsScand J Gastroenterol19963126068833356
   PubMed Web of Science ®Google Scholar
• LichtensteinGRKammMABodduPEffect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitisClin Gastroenterol Hepatol200759510217234558
   PubMed Web of Science ®Google Scholar
• LigumskyMKarmeliFSharonPEnhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazineGastroenterology19818144496114012
   PubMed Web of Science ®Google Scholar
• LimWCHanauerSBControversies with aminosalicylates in inflammatory bowel diseaseRev Gastroenterol Disord200441041715359211
   PubMedGoogle Scholar
• LoftusEVJrSilversteinMDSandbornWJUlcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survivalGut2000463364310673294
   PubMed Web of Science ®Google Scholar
• MansfieldJCHoldenHTarlowJKNovel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonistGastroenterology1994106637428119534
   PubMed Web of Science ®Google Scholar
• MinerPHanauerSRobinsonMSafety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study GroupDig Dis Sci1995402963047851193
   PubMed Web of Science ®Google Scholar
• ModiglianiRColombelJFDupasJLMesalamine in Crohn’s disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d’Etudes Therapeutiques des Affections Inflammatoires DigestivesGastroenterology1996110688938608877
   PubMed Web of Science ®Google Scholar
• MyersBEvansDNRhodesJMetabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tractGut1987281962003557190
   PubMed Web of Science ®Google Scholar
• NielsenOHSulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel diseaseScand J Gastroenterol198217389936127793
   PubMed Web of Science ®Google Scholar
• PokrotnieksJMarliczKParadowskiLEfficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled studyAliment Pharmacol Ther2004141191810971236
   PubMed Web of Science ®Google Scholar
• PranteraCViscidoABianconeLA new oral delivery system for 5-ASA: preliminary clinical findings for MMxInflamm Bowel Dis2005114212715867580
   PubMed Web of Science ®Google Scholar
• RachmilewitzDCoated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trialBMJ19892988262563951
   PubMed Web of Science ®Google Scholar
• RileySAManiVGoodmanMJComparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitisGastroenterology1988a94138392896139
   PubMed Web of Science ®Google Scholar
• RileySAManiVGoodmanMJComparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapseGut1988b29669742899536
   PubMed Web of Science ®Google Scholar
• SafdiMDeMiccoMSninskyCA double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitisAm J Gastroenterol1997921867719382054
   PubMed Web of Science ®Google Scholar
• SandbornWJHanauerSBSystematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitisAliment Pharmacol Ther200317294212492730
   PubMed Web of Science ®Google Scholar
• SantucciLWallaceJMencarelliADifferent sensitivity of lamina propria T-cell subsets to nitric oxide-induced apoptosis explains immunomodulatory activity of a nitric oxide-releasing derivative of mesalamine in rodent colitisGastroenterology200512812435715887108
   PubMed Web of Science ®Google Scholar
• ShaleMJRileySAStudies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel diseaseAliment Pharmacol Ther200318191812869079
   PubMed Web of Science ®Google Scholar
• SingletonJWHanauerSBGitnickGLMesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Pentasa Crohn’s Disease Study GroupGastroenterology199310412933018482443
   PubMed Web of Science ®Google Scholar
• SninskyCACortDHShanahanFOral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter studyAnn Intern Med199111535051863024
   PubMed Web of Science ®Google Scholar
• SutherlandLMacdonaldJKOral 5-aminosalicylic acid for induction of remission in ulcerative colitisCochrane Database Syst Rev (2)2006aCD000543
   Google Scholar
• SutherlandLMacdonaldJKOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisCochrane Database Syst Rev, (2)2006bCD000544
   Google Scholar
• SutherlandLRothDBeckPOral 5-aminosalicylic acid for inducing remission in ulcerative colitisCochrane Database Syst Rev 22000
   Google Scholar
• SutherlandLRothDBeckPOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisCochrane Database Syst Rev, (4)2002CD000544
   Google Scholar
• SutherlandLRMartinFBaileyRJA randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn’s disease. The Canadian Mesalamine for Remission of Crohn’s Disease Study GroupGastroenterology19971121069779097988
   PubMed Web of Science ®Google Scholar
• The Mesalamine Study GroupAn oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study GroupAnn Intern Med1996124204118533995
   PubMed Web of Science ®Google Scholar
• TravisSPTyskCde SilvaHJOptimum dose of olsalazine for maintaining remission in ulcerative colitisGut199435128267959238
   PubMed Web of Science ®Google Scholar
• van HeesPAvan TongerenJHCompliance to therapy in patients on a maintenance dose of sulfasalazineJ Clin Gastroenterol1982433366126499
   PubMed Web of Science ®Google Scholar
• WenZFiocchiCInflammatory bowel disease: autoimmune or immune-mediated pathogenesis?Clin Dev Immunol20041119520415559364
   PubMedGoogle Scholar
• WrightJPO’KeefeEACumingLOlsalazine in maintenance of clinical remission in patients with ulcerative colitisDig Dis Sci1993381837428404404
   PubMed Web of Science ®Google Scholar
• YangHRotterJIToyodaHUlcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markersJ Clin Invest199392108048349790
   PubMed Web of Science ®Google Scholar